Leqvio FDA Approval

A1 Adherence - real-world challenges compromise outcomes4 Statin adherence in secondary prevention¹ Not adherent² Adherent 43% 57% Non-adherent PCSK9i patient share³ 54% 12 months 76% 24 months Sustained lipid lowering reduces CV risk¹ MACE according to adherence categories in secondary prevention Cumulative incidence, % 45- 40 35 30 25 20 15- 10- 5. Log-Rank P value=.0002 0 6 12 18 24 30 36 42 Time in months Number 4015 3541 2421 1510 871 438 99 0 at risk PDC <40% PDC 40%-79% PDC ≥80% CV Cardiovascular MACE -Major Adverse Cardiovascular Event 2. Not adherent or not fully adherent within 6 months. 3. Data on file. PCSK9i - Proprotein convertase subtilisin/kexin type 9 inhibitor. PDC Percent Days Covered 1. Bansilal S, et al. J Am Coll Cardiol. 2016;68:789-801. 4. The effect of Leqvio® on cardiovascular morbidity and mortality is currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials. 18 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation V NOVARTIS | Reimagining Medicine

View entire presentation